EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent advances in the treatment of refractory gastrointestinal angiodysplasia

Aymeric Becq iD, Reena Sidhu, Lia C M J Goltstein, Xavier Dray iD

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12648 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Aymeric Becq und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Paris-Est Créteil University, Henri Mondor Hospital, AP HP, Créteil, France. Hauptthemen laut MEDLINE: Angiodysplasia, Gastrointestinal Hemorrhage, Angiogenesis Inhibitors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal angiodysplasia (GIA) is a common, acquired, vascular abnormality of the digestive tract, and a frequent cause of bleeding. Refractory GIA criteria usually include recurrent bleeding, transfusions and/or repeat endoscopy. Pharmacological and interventional treatments have been the subject of recent high‐quality publications. This review provides an overview of the latest updates on non‐endoscopic management of refractory GIA. Aortic valve replacement has shown its efficacy in Heyde syndrome and should be considered if indicated. Anti‐angiogenic drugs, such as Octreotide and Thalidomide, are efficient treatments of refractory GIA‐related bleeding. Somatostatin analogs should, based on efficacy and tolerance profile, be considered first. In the future, a better understanding of the physiopathology of GIA might help develop new‐targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AngiodysplasiaGastrointestinal HemorrhageAngiogenesis InhibitorsHumansSomatostatinOctreotideThalidomideGastrointestinal Agents

Stichwörter der Autor:innen

angiodysplasiaaortic valve replacementbevacizumabgastrointestinal bleedingsomatostatin analogsthalidomidetranscatheter aortic valve implantation

Substanzen

Angiogenesis InhibitorsSomatostatinOctreotideThalidomideGastrointestinal Agents

Autor:innen und Institutionen

  • Gastroenterology Department, Paris-Est Créteil University, Henri Mondor Hospital, AP HP, Créteil, France.
  • Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
  • Academic Unit of Gastroenterology and Hepatology, Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, UK.
  • Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Sorbonne University, Center for Digestive Endoscopy, Saint Antoine Hospital, AP HP, Paris, France.

ORCID-Profile: Aymeric Becq, Xavier Dray

Zitieren

APA

Becq, A., Sidhu, R., Goltstein, L. C. M. J., & Dray, X. (2024). Recent advances in the treatment of refractory gastrointestinal angiodysplasia. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12648

Vancouver

Becq A, Sidhu R, Goltstein LCMJ, Dray X. Recent advances in the treatment of refractory gastrointestinal angiodysplasia. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12648

BibTeX
@article{Becq2024,
  author = {Becq, Aymeric and Sidhu, Reena and Goltstein, Lia C M J and Dray, Xavier},
  title = {Recent advances in the treatment of refractory gastrointestinal angiodysplasia},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12648}
}
Kostenlos starten →